ASCO 2024: Adcetris performs well in classical Hodgkin lymphoma trial

3 June 2024
biotech_research_lab_vials_big

Japanese pharma giant Takeda (TYO: 4502) and Pfizer (NYSE: PFE) have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO).

The four-year analysis of the trial showed that Adcetris (brentuximab vedotin) combined with chemotherapy improved progression-free survival (PFS) and tolerability compared to a standard treatment in Europe.

This study involved patients with newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology